Jean Jacques Bienaime Acquires 10,500 Shares of Immunome (NASDAQ:IMNM) Stock

Immunome, Inc. (NASDAQ:IMNM) Director Jean Jacques Bienaime bought 10,500 shares of the company’s stock in a transaction on Friday, June 5th. The stock was bought at an average cost of $19.45 per share, for a total transaction of $204,225.00. Following the completion of the transaction, the director directly owned 43,415 shares of the company’s stock, valued at $844,421.75. This trade represents a 31.90% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Jean Jacques Bienaime also recently made the following trade(s):

• On Friday, May 15th, Jean Jacques Bienaime bought 5,000 shares of Immunome stock. The stock was bought at an average cost of $20.70 per share, for a total transaction of $103,500.00.
• On Wednesday, March 11th, Jean Jacques Bienaime bought 1,000 shares of Immunome stock. The stock was bought at an average cost of $21.55 per share, for a total transaction of $21,550.00.

Immunome Price Performance

Shares of NASDAQ IMNM opened at $18.16 on Thursday. Immunome, Inc. has a 1-year low of $7.96 and a 1-year high of $27.65. The business’s fifty day moving average price is $21.92 and its two-hundred day moving average price is $21.71. The firm has a market capitalization of $2.06 billion, a PE ratio of -7.63 and a beta of 2.04.

Immunome (NASDAQ:IMNM) last issued its quarterly earnings results on Tuesday, May 12th. The company reported ($0.48) EPS for the quarter, beating analysts’ consensus estimates of ($0.60) by $0.12. Equities research analysts expect that Immunome, Inc. will post -2.06 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. KBC Group NV bought a new position in Immunome during the first quarter valued at about $60,000. Strs Ohio bought a new position in Immunome during the fourth quarter valued at about $64,000. Assetmark Inc. bought a new position in Immunome during the third quarter valued at about $39,000. Aster Capital Management DIFC Ltd bought a new position in Immunome during the fourth quarter valued at about $121,000. Finally, BIT Capital GmbH bought a new position in Immunome during the third quarter valued at about $69,000. Institutional investors own 44.58% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on IMNM. Wall Street Zen lowered Immunome from a “hold” rating to a “sell” rating in a report on Saturday, May 30th. Barclays began coverage on Immunome in a report on Thursday, May 28th. They set an “overweight” rating and a $36.00 price target on the stock. Craig Hallum raised their price target on Immunome from $33.00 to $36.00 and gave the company a “buy” rating in a report on Wednesday, March 4th. Truist Financial raised their price target on Immunome from $36.00 to $37.00 and gave the company a “buy” rating in a report on Thursday, May 28th. Finally, HC Wainwright reissued a “buy” rating and set a $40.00 price target on shares of Immunome in a report on Wednesday, May 13th. Twelve investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Immunome presently has an average rating of “Moderate Buy” and a consensus target price of $33.17.

Immunome Company Profile

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.